References
1. Minnema MC, Kimby E, D’Sa S, Fornecker L-M, Poulain S, Snijders TJ,
et al. Guideline for the diagnosis, treatment and response criteria for
Bing-Neel syndrome. Haematologica. 2017;102(1):43-51.
2. Varettoni M, Defrancesco I, Diamanti L, Marchioni E, Farina LM,
Pichiecchio A. Bing-Neel Syndrome: Illustrative Cases and Comprehensive
Review of the Literature. Mediterranean journal of hematology and
infectious diseases. 2017;9(1):e2017061-e.
3. Simon L, Fitsiori A, Lemal R, Dupuis J, Carpentier B, Boudin L, et
al. Bing-Neel syndrome, a rare complication of Waldenström
macroglobulinemia: analysis of 44 cases and review of the literature. A
study on behalf of the French Innovative Leukemia Organization (FILO).
Haematologica. 2015;100(12):1587-94.
4. Fitsiori A, Fornecker LM, Simon L, Karentzos A, Galanaud D, Outteryck
O, et al. Imaging spectrum of Bing-Neel syndrome: how can a radiologist
recognise this rare neurological complication of Waldenström’s
macroglobulinemia? Eur Radiol. 2019;29(1):102-14.
5. Matsuda S, Sekiguchi N, Ito K, Takaoka K, Furuki M, Hirano K, et al.
An Autopsy Case of Bing-Neel Syndrome: Discrepancy between the
Radiological and Pathological Findings. Intern Med. 2019;58(13):1947-51.
6. Castillo JJ, Treon SP. How we manage Bing–Neel syndrome. British
Journal of Haematology. 2019;187(3):277-85.
7. Nagaharu K, Miyazami K, Imai H, Tamura A, Umino A, Fujieda A, et al.
[Successful treatment of Bing-Neel syndrome using combination therapy
with fludarabine and rituximab]. Rinsho Ketsueki. 2014;55(12):2423-8.
8. Gavriatopoulou M, Ntanasis-Stathopoulos I, Moulopoulos LA, Manaios A,
Fotiou D, Eleutherakis-Papaiakovou E, et al. Treatment of Bing-Neel
syndrome with first line sequential chemoimmunotherapy: A case report.
Medicine (Baltimore). 2019;98(44):e17794.
9. Poulain S, Boyle EM, Roumier C, Demarquette H, Wemeau M, Geffroy S,
et al. MYD88 L265P mutation contributes to the diagnosis of Bing Neel
syndrome. Br J Haematol. 2014;167(4):506-13.
10. Bernard S, Goldwirt L, Amorim S, Brice P, Brière J, de Kerviler E,
et al. Activity of ibrutinib in mantle cell lymphoma patients with
central nervous system relapse. Blood. 2015;126(14):1695-8.
11. Chamoun K, Choquet S, Boyle E, Houillier C, Larrieu-Ciron D, Al
Jijakli A, et al. Ibrutinib monotherapy in relapsed/refractory CNS
lymphoma: A retrospective case series. Neurology. 2017;88(1):101-2.
12. Cabannes-Hamy A, Lemal R, Goldwirt L, Poulain S, Amorim S, Pérignon
R, et al. Efficacy of ibrutinib in the treatment of Bing–Neel syndrome.
American Journal of Hematology. 2016;91(3):E17-E9.
13. O’Neil DS, Francescone MA, Khan K, Alobeid B, Bachir A, O’Connor OA,
et al. A Case of Bing-Neel Syndrome Successfully Treated with Ibrutinib.
Case reports in hematology. 2018;2018:8573105-.
14. Castillo JJ, D’Sa S, Lunn MP, Minnema MC, Tedeschi A, Lansigan F, et
al. Central nervous system involvement by Waldenström macroglobulinaemia
(Bing-Neel syndrome): a multi-institutional retrospective study. Br J
Haematol. 2016;172(5):709-15.